Technology News and Research

RSS

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study. The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

30 Sep 2010

New caproKits enable investigation of small molecule–protein interactions

caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits, enabling the discovery, identification and characterization of proteins for applications in functional proteomics and drug development.

30 Sep 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

Warburg Pincus to invest CDN $35 million in Protox

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.

30 Sep 2010

Kaiser Permanente donates Convergent Medical Terminology to IHTSDO

Kaiser Permanente today donated its Convergent Medical Terminology (CMT) to the International Healthcare Terminology Standards Development Organisation (IHTSDO) for U.S. distribution through the U.S. Department of Health and Human Services (HHS) so that all health care providers arge and small can benefit from the translation-enabling technology.

30 Sep 2010

Two new techniques to identify dissolved cocaine in bottles of wine or rum

In two landmark studies published today in the journal Drug Testing and Analysis (DTA), UK and Swiss research teams reveal two techniques proven to identify dissolved cocaine in bottles of wine or rum. These tools will allow customs officials to quickly identify bottles being used to smuggle cocaine, without the need to open or disturb the container.

30 Sep 2010

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon™ flu vaccine development.

30 Sep 2010

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Scientists use NMR technology to improve protein purification in drug development

The purification of drug components is a large hurdle facing modern drug development. This is particularly true of drugs that utilize proteins, which are notoriously difficult to separate from other potentially deadly impurities. Scientists within the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer Polytechnic Institute are using nuclear magnetic resonance (NMR) to understand and improve an important protein purification process.

30 Sep 2010

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

Mount Sinai School of Medicine received a contract for almost $16.5 million from The National Institutes of Health (NIH) and the National Heart and Lung Institute (NHLBI) through the Program of Excellence in Nanotechnology (PEN). The contract is one of four issued nationally to develop multidisciplinary research Centers with the goal of developing nanotechnology tools for diagnosing and treating heart, lung and blood diseases.

30 Sep 2010

New miRNA screening assay to detect early-stage colorectal cancer

A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S

30 Sep 2010

McLean Researchers receive award to create first clinic-ready human induced iPS cells

Belmont, MA-Researchers at Harvard Affiliated McLean Hospital have been awarded a $1.9 million National Institutes of Health Director's Opportunity Award to continue their research into creating human induced pluripotent (iPS) stem cells using a method aimed at eliminating the risk of cancer and other problems associated with other options such as genome-integrating viral methods.

30 Sep 2010

BSD receives patent for heat therapy applicators

BSD Medical Corporation announced today that a patent has been issued to the Company for a new class of heat therapy applicators (antennas). The United States (US) patent office issued the new patent, Transparent electromagnetic applicator and hyperthermia treatment method, to BSD for a unique design for antennas that provides significant benefits for heat therapy applications.

30 Sep 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

Radiologists urge judicious use of radiation-based imaging in children

A CT scan can mean the difference between an accurate and a wrong diagnosis, timely and delayed treatment and, in some cases, life and death. But because CT scans and other tests that use X-ray technology expose the body to often large doses of radiation, their unnecessary, repeated and excessive use may increase cancer risk, especially in children.

30 Sep 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers have identified a novel, dual-platform technology, the On-Q-ity Circulating Cancer Capture and Characterization Chip (C5), which they believe is more efficient than the commonly used single-platform device in identifying circulating tumor cells (CTCs) in breast cancer.

30 Sep 2010

Researchers develop genetic screening method to identify drug-resistant HCV strains

In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.

30 Sep 2010

Technology News and Research

Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

New caproKits enable investigation of small molecule–protein interactions

Cardium expands wound healing and tissue regeneration portfolio

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Warburg Pincus to invest CDN $35 million in Protox

Kaiser Permanente donates Convergent Medical Terminology to IHTSDO

Two new techniques to identify dissolved cocaine in bottles of wine or rum

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

AccuPSA test for detecting prostate cancer recurrence

Circassia announces advancement in T-cell allergy vaccines development

Scientists use NMR technology to improve protein purification in drug development

Mount Sinai receives contract to develop nanotechnology tools for diagnosing diseases

New miRNA screening assay to detect early-stage colorectal cancer

McLean Researchers receive award to create first clinic-ready human induced iPS cells

BSD receives patent for heat therapy applicators

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

Radiologists urge judicious use of radiation-based imaging in children

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Researchers develop C5 technology to identify CTCs in breast cancer

Researchers develop genetic screening method to identify drug-resistant HCV strains

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News